Zavegepant, a third-generation, high-affinity, selective and structurally unique, small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is the only intranasal CGRP receptor antagonist in late-stage development for the acute treatment of migraine. Findings from a previous single ascending dose study indicated that intranasal zavegepant produced potentially therapeutic systemic exposures.